WeekScoop

Why Standard Cholesterol Testing Is Incomplete

When your doctor orders a cholesterol panel, the numbers you get are total cholesterol, LDL cholesterol (often calculated, not measured), HDL cholesterol, and triglycerides. These four numbers have been the foundation of cardiovascular risk assessment for decades, and they are useful — but they tell you very little about the actual risk profile of the cholesterol particles circulating in your blood. Two people with identical LDL cholesterol numbers can have dramatically different cardiovascular risk profiles depending on the size, density, and number of their LDL particles, the inflammation in their arterial walls, and the functionality of their HDL particles. Standard cholesterol panels miss all of this.

The Pattern That Matters: LDL Size

LDL cholesterol exists in multiple subtypes that differ in size, density, and atherogenic potential. Small, dense LDL particles (pattern B) are highly atherogenic — they easily penetrate the arterial wall, become oxidised, and initiate the inflammatory cascade that leads to atherosclerotic plaque formation. Large, buoyant LDL particles (pattern A) are far less likely to do this. A person with high LDL cholesterol but predominantly large, buoyant LDL particles (common if they have a clean diet and moderate alcohol consumption) has significantly lower cardiovascular risk than a person with the same LDL number but predominantly small, dense particles (common in insulin resistance, metabolic syndrome, and type 2 diabetes).

The primary driver of the shift from large, buoyant to small, dense LDL particles is insulin resistance. Insulin resistance promotes the activity of hepatic lipase — an enzyme that breaks down larger LDL particles into smaller, denser ones. This means that insulin resistance — which is present in a large proportion of the overweight and metabolically unhealthy population — is simultaneously driving the production of the most atherogenic form of LDL cholesterol. This is why cardiovascular risk assessment is incomplete without some assessment of metabolic health: a person with metabolic syndrome and normal LDL numbers can have higher cardiovascular risk than a person with elevated LDL but no metabolic dysfunction.

What Actually Causes Small, Dense LDL

The diet and lifestyle factors that promote small, dense LDL are the same factors that drive insulin resistance: high-carbohydrate diets, particularly refined carbohydrates and added sugars; excess body fat, particularly visceral adiposity; physical inactivity; and alcohol consumption. The good news is that the same interventions that improve insulin sensitivity — reducing refined carbohydrates, resistance training, weight loss, adequate sleep — also shift LDL particle size back toward the larger, less atherogenic pattern. The mechanism is direct and fast: within weeks of dietary and lifestyle changes, LDL particle size distribution can measurably improve.

Testing for LDL Pattern

The standard lipid panel does not tell you your LDL particle size or number. A specialised NMR (nuclear magnetic resonance) lipometer test — available through standard blood draw at most major laboratories — provides LDL particle number (LDL-P) and particle size distribution. This is particularly worth requesting if you have any of the following: metabolic syndrome, type 2 diabetes, a family history of early cardiovascular disease, or normal LDL cholesterol numbers but high triglycerides (because this combination suggests the LDL is likely small and dense). Knowing the actual risk, rather than the surrogate marker, changes the intervention: a person with predominantly small, dense LDL has more urgent reason to address metabolic health than a person with the same LDL number but large, buoyant particles.

This article is for informational purposes only. Cardiovascular risk assessment should be discussed with your GP or cardiologist.

Reading Your Lipid Panel Correctly

When you get a standard lipid panel from your doctor, the most important numbers to understand are not just total cholesterol and LDL cholesterol. The full picture requires looking at triglycerides (elevated triglycerides are the hallmark of the metabolic dysfunction that drives small, dense LDL), HDL cholesterol (low HDL is part of the atherogenic dyslipidemia pattern), and the triglyceride to HDL ratio (a ratio above 2.5 is a strong marker of insulin resistance and the associated atherogenic LDL pattern, calculable from any standard lipid panel).

If your triglycerides are elevated and your HDL is low, you almost certainly have the metabolic driver of small, dense LDL, regardless of what your LDL cholesterol number shows. You do not need an NMR test to know that you need to address your metabolic health. The NMR test provides additional information about LDL particle number and size, but it does not change the action plan: improve insulin sensitivity through diet, exercise, and weight management.

The Cardiovascular Risk You Cannot See on Standard Tests

Coronary artery calcification (CAC) scoring — a CT scan that measures the amount of calcium in the walls of the coronary arteries — is one of the most powerful cardiovascular risk assessment tools available, and it is available for under £150 in most UK private clinics. A CAC score of zero indicates essentially no measurable atherosclerotic plaque and carries an excellent prognosis for the next five years. A CAC score above 100 indicates significant plaque burden and a substantially elevated risk of cardiovascular events over the next decade.

The CAC score is independent of blood cholesterol levels — you can have a CAC score of 400 with normal LDL cholesterol, because the plaque in your arterial walls is driven by inflammation and metabolic dysfunction, not just by circulating cholesterol. This is why cardiovascular risk assessment is incomplete without some imaging of the actual arteries. For anyone with an atherogenic lipid pattern (high triglycerides, low HDL) or a family history of early cardiovascular disease, requesting a CAC score is a reasonable investment in understanding their actual risk.

The combination of a standard lipid panel, a CAC score, and an assessment of metabolic health (fasting insulin, HbA1c, inflammatory markers like high-sensitivity CRP) gives a comprehensive picture of cardiovascular risk that goes well beyond what LDL cholesterol alone can tell you. This is not expensive testing — most of it is available through standard NHS GP services — and it changes the intervention. A person with a CAC score of zero and elevated LDL cholesterol needs different risk management than a person with a CAC score of 300 and “normal” LDL cholesterol, even if their lipid panels look similar on the surface.